Calliditas Therapeutics received the award in recognition of its successful clinical development program of Nefecon, which culminated in the recent positive topline data readout of the Phase 3 NefIgArd trial.
“This year’s winner has shown impressive professionalism and staying power with regards to the development of a completely new treatment for patients with IgA Nephropathy, a disease which lacks approved treatments today. With positive Phase 3 results in place, preparations for a submission for regulatory approval and subsequent commercialization in the US are now underway,” says Lars Adlersson, Chairman of SwedenBIO.
Read more: Positive results from Calliditas
“We are delighted to have been selected for this prestigious award, which recognizes the company’s longstanding commitment to addressing a significant unmet medical need for patients with IgA Nephropathy. We look forward to continuing to build on this success to deliver solutions to patients with orphan diseases,” says Renée Aguiar-Lucander, CEO, Calliditas.
Increase visibility for the life science industry
SwedenBio annually awards this prize to a company which has excelled in terms of R&D, business development and growth whilst contributing to societal benefit.
The SwedenBIO Award aims to increase visibility for the life science industry by drawing attention to and rewarding successful and exemplary member companies that have particularly excelled and contributed to positive attention for the industry. A record number of companies were nominated for this year’s award.
Image caption: Johan Christenson, partner, HealthCap, Renée Aguiar-Lucander, CEO Calliditas Therapeutics and Lars Adlersson, Chairman of SwedenBIO.
Photo: SwedenBIO
